Kombivichvak has passed the first phase of clinical trials

Novosibirsk Scientific Center has successfully completed the first phase of HIV vaccine trials

RIA Novosti, Dmitry Mikhalev.

The State Scientific Center of Virology and Biotechnology "Vector" of Rospotrebnadzor (Novosibirsk) has successfully completed the first phase of clinical trials of a Russian vaccine against the human immunodeficiency virus, Alexander Sergeev, Director General of the center, told reporters on Monday.

"The Kombivichvak vaccine has passed the first stage of clinical trials. It stimulates both the humoral response of the body (the production of antibodies) and cellular, unlike those vaccines that are currently being developed in the world. Our vaccine combines both," he said.

According to Sergeyev, the tests showed good tolerability of the drug and the corresponding immune response of both the humoral and cellular link.

The CEO said that the decision to start the second phase of clinical trials should now be taken by the national control body – the Scientific Center for the Examination of Medical Products (Moscow).

"By the end of the first quarter of this year, we have to send (research results). They (NCESMP) decide whether to give us the second phase of research," Sergeyev said.

He said that there are all prerequisites for a positive decision, but there are difficulties, since currently there are no clear criteria for the effectiveness of such a vaccine in the world.

Portal "Eternal youth" http://vechnayamolodost.ru
06.02.2012